tiprankstipranks
Advertisement
Advertisement

McPherson’s trims costs, lifts cash as new operating model beds down despite 1H loss

Story Highlights
  • McPherson’s 1H26 revenue fell but core brands held steady, boosting EBITDA and cash.
  • Transition-related brand disruptions hurt profit, yet a new buyback signals strategic confidence.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
McPherson’s trims costs, lifts cash as new operating model beds down despite 1H loss

Meet Samuel – Your Personal Investing Prophet

Mcpherson’S Limited ( (AU:MCP) ) has issued an announcement.

McPherson’s reported revenue from continuing operations of $66.0 million for the half year to 31 December 2025, a 6.7% decline, but maintained largely stable core brand sales at $61.9 million as Manicare and Swisspers delivered solid growth while Dr LeWinn’s and Fusion Health lagged. The shift to a new operating model reduced fixed costs, lifting underlying EBITDA 10.6% to $2.2 million and supporting a net cash position of $12.6 million, despite a statutory net loss of $2.3 million driven by a non-cash impairment and one-off items.

Management highlighted that the transition to pharmacy wholesalers, SKU rationalisation, and logistics outsourcing caused temporary revenue and supply disruptions, particularly for Dr LeWinn’s and Fusion Health, but said corrective actions and restored stock levels should support gradual improvement in the second half. The board opted against paying a dividend but authorised an on-market share buyback of up to A$2.0 million, signalling confidence in the company’s strategy and the scalability of its new operating model for future growth and shareholder returns.

The most recent analyst rating on (AU:MCP) stock is a Hold with a A$0.19 price target. To see the full list of analyst forecasts on Mcpherson’S Limited stock, see the AU:MCP Stock Forecast page.

More about Mcpherson’S Limited

McPherson’s Limited is an ASX-listed consumer products company focused on health, wellness, and beauty brands sold primarily through pharmacy and grocery channels in Australia and selected international markets. Its core portfolio includes Manicare, Swisspers, Lady Jayne, Dr LeWinn’s, and Fusion Health, which together account for the vast majority of group sales and underpin its market positioning in everyday personal care and skincare categories.

Average Trading Volume: 263,385

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$27.35M

For detailed information about MCP stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1